RT Journal Article
SR Electronic
T1 Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1-nCoV19 and BNT162b2: a prospective cohort study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.19.21257334
DO 10.1101/2021.05.19.21257334
A1 David Hillus
A1 Tatjana Schwarz
A1 Pinkus Tober-Lau
A1 Hana Hastor
A1 Charlotte Thibeault
A1 Stefanie Kasper
A1 Elisa T. Helbig
A1 Lena J. Lippert
A1 Patricia Tscheak
A1 Marie Luisa Schmidt
A1 Johanna Riege
A1 André Solarek
A1 Christof von Kalle
A1 Chantip Dang-Heine
A1 Piotr Kopankiewicz
A1 Norbert Suttorp
A1 Christian Drosten
A1 Harald Bias
A1 Joachim Seybold
A1 EICOV/COVIM Study Group
A1 Claudia Conrad
A1 Doris Steuer
A1 Ute Gläser
A1 Anne-Sophie Sinnigen
A1 Carolin Rubisch
A1 Nadine Olk
A1 Lisbeth Hasler
A1 Angela Sanchez-Rezza
A1 Paolo Kronenberg
A1 Alexandra Horn
A1 Willi Koch
A1 Paula Stubbemann
A1 Julie-Anne Gabelich
A1 Friederike Münn
A1 Julia Tesch
A1 Petra Mackeldanz
A1 Leon Bergfeld
A1 Tobias Bleicker
A1 Jörn Ilmo Beheim-Schwarzbach
A1 Anna Hiller
A1 Sophia Brumhard
A1 Lara Bardtke
A1 Kai Pohl
A1 Daniel Wendisch
A1 Philipp Georg
A1 Denise Treue
A1 Dana Briesemeister
A1 Jenny Schlesinger
A1 Andreas Hetey
A1 Luisa Kegel
A1 Annelie Richter
A1 Ben Al-Rim
A1 Birgit Maeß
A1 Kerstin Behn
A1 Michelle Lysi
A1 Saskia Zvorc
A1 Maria Rönnefarth
A1 Sein Schmidt
A1 Alexander Krannich
A1 Isabelle Schellenberger
A1 Georg Schwanitz
A1 Viktoria Schenkel
A1 Norma Bethke
A1 Claudia Hülso
A1 Sebastian Dieckmann
A1 Christian Peiser
A1 Florian Kurth
A1 Victor Max Corman
A1 Leif Erik Sander
YR 2021
UL http://medrxiv.org/content/early/2021/06/02/2021.05.19.21257334.abstract
AB Objective to assess reactogenicity and immunogenicity of heterologous prime-boost immunisations of ChAdOx1-nCoV19 (Vaxzevria, ChAdOx) followed by BNT162b2 (Comirnaty, BNT) compared to homologous BNT/BNT immunisation.Design prospective, observational cohort study.Setting unicenter study in a cohort of health care workers at a tertiary care center in Berlin, Germany.Participants 340 health care workers immunised between 27 December 2020 and 21 May 2021 at Charité - Universitätsmedizin Berlin, GermanyMain outcome measures the main outcomes were reactogenicity assessed on days one, three, five and seven post prime and boost vaccination, and immunogenicity measured by serum SARS-CoV-2 full spike-, spike S1-, and spike RBD-IgG, virus neutralisation capacity, anti-S1-IgG avidity, and T cell reactivity measured by Interferon gamma release assay at 3-4 weeks post prime and boost immunisation.Results Heterologous ChAdOx/BNT booster vaccination was overall well-tolerated and reactogenicity was largely comparable to homologous BNT/BNT vaccination. Systemic reactions were most frequent after prime immunisation with ChAdOx (86%, 95CI: 79-91), and less frequent after homologous BNT/BNT (65%, 95CI: 56-72), or heterologous ChAdOx/BNT booster vaccination (48%, 95CI: 36-59). Serum antibody responses and T cell reactivity were strongly increased after both homologous and heterologous boost, and immunogenicity was overall robust, and comparable between both regimens in this cohort, with slightly increased S1-IgG avidity and T cell responses following heterologous booster immunisation.Conclusions Evidence of rare thrombotic events associated with ChAdOx has led to recommendation of a heterologous booster with mRNA vaccines for certain age groups in several European countries, despite a lack of robust safety and immunogenicity data for this vaccine regimen. This interim analysis provides evidence that the currently recommended heterologous ChAdOx/BNT immunisation regimen with 10-12 week vaccine intervals is well tolerated and slightly more immunogenic compared to homologous BNT/BNT vaccination with three week vaccine intervals. Heterologous prime-boost immunisation for COVID-19 may be generally applicable to optimise logistics and improve immunogenicity and to mitigate potential intermittent supply shortages for individual vaccines.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialEudraCT-No. 2021-001512-28Funding StatementSupported by the German Federal Ministry of Education and Research (BMBF) Forschungsnetzwerk der Universitaetsmedizin zu Covid-19 COVIM - FKZ: 01KX2021 (to L.E.S., V.M.C., F.K., C.D., N.S.).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:EICOV was approved by the ethics committee (IRB) of Charite - Universitaetsmedizin Berlin (EA4/245/20) and COVIM (EudraCT-No. 2021-001512-28) was approved by the Federal Institute for Vaccines and Biomedicines (Paul Ehrlich Institute) and by the Ethics committee of the state of Berlin.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is available upon reasonable request.